The state of complement in COVID-19

Behdad Afzali; Marina Noris; Bart N. Lambrecht; Claudia Kemper

doi:10.1038/s41577-021-00665-1

The state of complement in COVID-19

Behdad Afzali^*, Marina Noris^*, Bart N. Lambrecht^*, Claudia Kemper^*

^*Corresponding author for this work

Institute of Systemic Inflamation Research

120 Citations (Scopus)

Abstract

Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.

Original language	English
Journal	Nature Reviews Immunology
Volume	22
Issue number	2
Pages (from-to)	77-84
Number of pages	8
ISSN	1474-1733
DOIs	https://doi.org/10.1038/s41577-021-00665-1
Publication status	Published - 02.2022

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

DFG Research Classification Scheme

204-05 Immunology

Coronavirus related work

Research on SARS-CoV-2 / COVID-19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41577-021-00665-1

Cite this

@article{986e2747e140487c9c00fdcfdc5f9cac,

title = "The state of complement in COVID-19",

abstract = "Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.",

author = "Behdad Afzali and Marina Noris and Lambrecht, {Bart N.} and Claudia Kemper",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Nature Limited.",

year = "2022",

month = feb,

doi = "10.1038/s41577-021-00665-1",

language = "English",

volume = "22",

pages = "77--84",

journal = "Nature Reviews Immunology",

issn = "1474-1733",

number = "2",

}

TY - JOUR

T1 - The state of complement in COVID-19

AU - Afzali, Behdad

AU - Noris, Marina

AU - Lambrecht, Bart N.

AU - Kemper, Claudia

PY - 2022/2

Y1 - 2022/2

N2 - Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.

AB - Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85121549900&partnerID=8YFLogxK

U2 - 10.1038/s41577-021-00665-1

DO - 10.1038/s41577-021-00665-1

M3 - Journal articles

C2 - 34912108

AN - SCOPUS:85121549900

SN - 1474-1733

VL - 22

SP - 77

EP - 84

JO - Nature Reviews Immunology

JF - Nature Reviews Immunology

IS - 2

ER -

The state of complement in COVID-19

Abstract

Research Areas and Centers

DFG Research Classification Scheme

Coronavirus related work

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this